Webseite regulanet.com

Research and Markets (http://www.researchandmarkets.com/research/a69afe/health_and_wellnes) has announced the addition of the "Health and Wellness in Taiwan" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/523b78/cw_weekly) has announced the addition of the "CW Weekly" subscription to their offering.

Research and Markets (http://www.researchandmarkets.com/research/274a50/daily_updates_met) has announced the addition of the "Daily Updates: Metabolic Disorders - Tracking breaking research, drug development news new trials" subscription to their offering.

Research and Markets (http://www.researchandmarkets.com/research/257d46/alzheimers_diseas) has announced the addition of the "Alzheimers Disease Immunotherapy Pipeline: Vaccines, Therapeutic Antibodies and Emerging Strategies - 2010" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/72f06c/daily_updates_psy) has announced the addition of the "Daily Updates: Psychiatric Diseases - Tracking breaking research, drug development news new trials" subscription to their offering.

Research and Markets (http://www.researchandmarkets.com/research/b6905d/2010_cell_culture) has announced the addition of the "2010 Cell Culture Dashboard Series 3" report to their offering. The growth and propagation of mammalian cells in culture is a routine but critical precursor to the investigation of such fundamental cellular processes as gene expression and protein function and to the development of therapeutics. Cell culture products are widely used not only by scientists working with traditional cell lines but also by researchers engaged in experiments with such emerging model systems as stem cells and engineered cell lines. This Cell Culture Dashboard was developed based upon the aggregated responses to a 22-question survey completed by more than 480 scientists actively engaged in mammalian cell culture predominantly located in North America and Europe. This Dashboard reveals key market indicators for the research market for cell culture products as a whole as well as for the following product segments:

Research and Markets (http://www.researchandmarkets.com/research/41867b/cancer_drug_resist) has announced the addition of the "Cancer Drug Resistance" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/fe918c/daily_updates_dia) has announced the addition of the "Daily Updates: Diagnostics & Devices - Tracking breaking research, drug development news new trials" subscription to their offering.

Research and Markets (http://www.researchandmarkets.com/research/e3fec8/mens_health_thera) has announced the addition of the "Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/61183d/womens_health_the) has announced the addition of the "Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/58e6b3/altea_therapeutics) has announced the addition of the "Altea Therapeutics-Detailed Product Pipeline" company profile to their offering.

Research and Markets (http://www.researchandmarkets.com/research/2fb050/abbott_india_limit) has announced the addition of the "Abbott India Limited-Detailed Product Pipeline" company profile to their offering.

Research and Markets (http://www.researchandmarkets.com/research/d138a1/lundbeck_inc_for) has announced the addition of the "Lundbeck Inc. (formerly Ovation Pharmaceuticals, Inc.)-Detailed Product Pipeline" company profile to their offering.

Research and Markets (http://www.researchandmarkets.com/research/1027aa/lincoln_pharmaceut) has announced the addition of the "Lincoln Pharmaceuticals Ltd-Detailed Product Pipeline" company profile to their offering.

Research and Markets (http://www.researchandmarkets.com/research/234d9d/belarus_pharmaceut) has announced the addition of the "Belarus Pharmaceuticals and Healthcare Report Q3 2010" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/4b2a2f/pharmaceutical_con) has announced the addition of the "Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/d49073/diagnostic_imaging) has announced the addition of the "Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/6e510d/manufacturing_of_b) has announced the addition of the "Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies" report to their offering.

Regulatory News:

Accentus Medical, a leading UK medical technology company that supplies advanced coatings and surface treatments to the medical device industry, announced today that it has signed a Licence and Services Agreement with Zimmer Holdings, Inc., a global market leader in musculoskeletal care. This agreement will enable the use of Accentus Medical's Agluna^® anti-infective technology on a potentially broad range of Zimmer products.

Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than €190m ($240m). Forbion's €54m Co-Invest Fund aims to invest alongside FCF I in a select number of late-stage FCF I portfolio companies. FCF II has an investment strategy similar to its predecessor fund FCF I. Forbion aims to invest the majority of the fund in Europe and the remainder in North America and Israel. The investment focus is on private companies developing novel drugs, medical devices and diagnostics for high- or even unmet medical needs. This is serving a market that is both driven by the pharmaceutical industry's continued need for new products to supplement their ailing pipelines as well as by patient demand for safer and more efficacious treatments.

Research and Markets (http://www.researchandmarkets.com/research/2c2bf4/health_and_wellnes) has announced the addition of the "Health and Wellness in Norway" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/e1e09f/health_and_wellnes) has announced the addition of the "Health and Wellness in Greece" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/800c06/health_and_wellnes) has announced the addition of the "Health and Wellness in Finland" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/b4eb0f/health_and_wellnes) has announced the addition of the "Health and Wellness in Denmark" report to their offering.

Die Europäische Kommission hat den Zulassungsantrag für SYCREST^® (Asenapin) Sublingualtabletten für die Behandlung von mittelstark bis stark ausgeprägten manischen Episoden in Zusammenhang mit einer Bipolar-I-Störung bei Erwachsenen bewilligt. Das gab MSD (MSD ist ein Handelsname von Merck & Co., Inc., mit Hauptniederlassung in Whitehouse Station, New Jersey, USA) heute bekannt. Bei der heutigen Entscheidung ist man den Empfehlungen des Ausschusses für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) gefolgt. Die Entscheidung der Kommission gilt für alle 27 europäischen Mitgliedstaaten.

Research and Markets (http://www.researchandmarkets.com/research/79eb51/searle_pakistan_lt) has announced the addition of the "Searle Pakistan LTD.-Detailed Product Pipeline" company profile to their offering.

Research and Markets (http://www.researchandmarkets.com/research/d9793d/pharmatec_pakistan) has announced the addition of the "Pharmatec Pakistan (private) Limited-Detailed Product Pipeline" company profile to their offering.

A group of Glasgow lawyers are swapping the courts for the track, as they are taking part in a sponsored run to raise money for a vital Scottish health service.